AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

November 19, 2019

WATERTOWN, Mass.--(BUSINESS WIRE)--Nov 19, 2019--

Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s 2017 Equity Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4).

The Company granted stock options to purchase up to an aggregate of 16,000 shares of Kala Pharmaceuticals common stock to three new employees. The stock options were granted on November 15, 2019. The grant was approved by the Compensation Committee and was made as an inducement material to each employee entering into employment with Kala Pharmaceuticals in accordance with NASDAQ Listing Rule 5635(c)(4). The option awards have an exercise price of $3.69 per share, the closing price of Kala Pharmaceuticals’ common stock on November 15, 2019. The options have a ten-year term and vest over four years, with 25% of the original number of shares vesting on the first anniversary of the applicable employee’s new hire date and the remainder vesting in equal monthly installments over the following three years. Vesting of each option is subject to such employee’s continued service with Kala Pharmaceuticals through the applicable vesting dates.

About Kala Pharmaceuticals, Inc.

Kala is a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary AMPPLIFY™ mucus-penetrating particle (MPP) Drug Delivery Technology, with an initial focus on the treatment of eye diseases. Kala has applied the AMPPLIFY Drug Delivery Technology to a corticosteroid, loteprednol etabonate (LE), designed for ocular applications, resulting in the August 2018 FDA approval of INVELTYS ® (loteprednol etabonate ophthalmic suspension) 1% for the treatment of inflammation and pain following ocular surgery and its lead product candidate, EYSUVIS™ (loteprednol etabonate ophthalmic suspension) 0.25%, for the temporary relief of the signs and symptoms of dry eye disease.

View source version on businesswire.com:https://www.businesswire.com/news/home/20191119005137/en/

CONTACT: Investors

Hannah Deresiewicz, 212-362-1200

Hannah.Deresiewicz@sternir.comMedia

Kari Watson, 781-235-3060

kwatson@macbiocom.com

KEYWORD: MASSACHUSETTS UNITED STATES NORTH AMERICA

INDUSTRY KEYWORD: BIOTECHNOLOGY PHARMACEUTICAL OPTICAL HEALTH

SOURCE: Kala Pharmaceuticals, Inc.

Copyright Business Wire 2019.

PUB: 11/19/2019 04:05 PM/DISC: 11/19/2019 04:05 PM

http://www.businesswire.com/news/home/20191119005137/en